Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Christos G Papadopoulos"'
Autor:
Vassilios Moussis, Vassilios Tsikaris, Evgenia Fotou, Savvas Christoforidis, Sofia Zografou, Panos Kouklis, Christos G Papadopoulos, Alaxandra Ntoyhaniari, Violetta Maltabe
Publikováno v:
Journal of Peptide Science. 27
The generation of cell-penetrating peptides as cargo-delivery systems has produced an immense number of studies owing to the importance of these systems as tools to deliver molecules into the cells, as well as due to the interest to shed light into a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6c76ec714061877a59f4e5e12d2beb4
https://doi.org/10.1002/psc.3359
https://doi.org/10.1002/psc.3359
Autor:
Ilias K Gartzonikas, Christos G Papadopoulos, Tatiani K Pappa, Michael P Migkos, Alexandros A. Drosos, Theodora E. Markatseli, Paraskevi V. Voulgari
Publikováno v:
Rheumatology Advances in Practice
Objective. This study aimed to investigate the efficacy, safety and survival of TNF-α inhibitors in patients with RA. Methods. A total of 178 patients >18 years of age were treated with TNF-α inhibitors. A total of 74 patients were treated with inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08444a2b8d5e02a6bd13bae1e7f0b5b0
https://pubmed.ncbi.nlm.nih.gov/31431995
https://pubmed.ncbi.nlm.nih.gov/31431995
Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis
Autor:
Alexandros A. Drosos, Theodora E. Markatseli, Christos G Papadopoulos, Aliki I. Venetsanopoulou, Paraskevi V. Voulgari, Yannis Alamanos
Publikováno v:
Rheumatology International. 27:935-939
Our aim was to investigate the efficacy, toxicity, and drug discontinuation in patients with ankylosing spondylitis (AS) treated with infliximab. Thirty-five patients with AS, who were enrolled between June 2001 and December 2002 were treated with in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2d468816d31b086d1890b764a4202a8
https://doi.org/10.1007/s00296-007-0330-9
https://doi.org/10.1007/s00296-007-0330-9
Autor:
Christos G Papadopoulos, Paraskevi V. Voulgari, Alexandros A. Drosos, Spyros N Nikas, A N Georgiadis, Yannis Alamanos, Aliki I. Venetsanopoulou
Publikováno v:
Annals of the Rheumatic Diseases. 65:257-260
OBJECTIVE: To describe the efficacy and safety of adalimumab in patients with rheumatoid arthritis (RA) who had previously discontinued infliximab treatment. METHODS: 24 patients with RA who discontinued treatment with infliximab (switchers) were tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34776e3bc67e4312253a2affe0267e9e
https://doi.org/10.1136/ard.2005.039099
https://doi.org/10.1136/ard.2005.039099
Autor:
Ioannis Georgiou, Alexandros A. Drosos, Anthoula Chatzikyriakidou, Christos G Papadopoulos, Paraskevi V. Voulgari, Theodoros Tzavaras
Publikováno v:
Rheumatology international. 27(11)
The reduced folate carrier (RFC) protein (SLC19A1-gene) has central role in the uptake and intracellular accumulation of folates. In this respect, we investigate whether SLC19A1 genetic variations could affect rheumatoid arthritis (RA) patient respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebd025695ec42431304407eb6bbf8b84
https://pubmed.ncbi.nlm.nih.gov/17404734
https://pubmed.ncbi.nlm.nih.gov/17404734
Autor:
Christos G Papadopoulos, Paraskevi V. Voulgari, Spyros N Nikas, Yannis Alamanos, Xanthi Pliakou, Alexandros A. Drosos
Publikováno v:
Annals of the rheumatic diseases. 64(6)
Objective: To investigate efficacy, toxicity, and drug discontinuation in patients with ankylosing spondylitis (AS) treated with infliximab. Methods: 35 patients with AS with mean (SD) age 42.5 (12.6) years and mean (SD) disease duration 14.5 (8.0) y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3f2e92062a5b318e92e676b7384c911
https://pubmed.ncbi.nlm.nih.gov/15564309
https://pubmed.ncbi.nlm.nih.gov/15564309